Works matching IS 11707690 AND DT 2013 AND VI 31 AND IP 5

Results: 11

The Authors' Reply to van Baal et al.: 'Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.'.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 375, doi. 10.1007/s40273-013-0046-5

By:

Grima, Daniel;
Bernard, Lisa;
Dunn, Elizabeth;
McFarlane, Philip;
Mendelssohn, David

Publication type:

Article

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.

Published in:

2013

By:

Greenhalgh, Janette;
Bagust, Adrian;
Boland, Angela;
Blundell, Michaela;
Oyee, James;
Beale, Sophie;
Dundar, Yenal;
Hockenhull, Juliet;
Proudlove, Chris;
Chu, Patrick

Publication type:

journal article

How Much Should the NHS Pay for a QALY?

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 357, doi. 10.1007/s40273-013-0062-5

By:

Haycox, Alan

Publication type:

Article

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 427, doi. 10.1007/s40273-013-0048-3

By:

Simpson, Kit;
Pei, Pamela;
Möller, Jörgen;
Baran, Robert;
Dietz, Birgitta;
Woodward, William;
Migliaccio-Walle, Kristen;
Caro, J.

Publication type:

Article

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 361, doi. 10.1007/s40273-013-0032-y

By:

Husereau, Don;
Drummond, Michael;
Petrou, Stavros;
Carswell, Chris;
Moher, David;
Greenberg, Dan;
Augustovski, Federico;
Briggs, Andrew;
Mauskopf, Josephine;
Loder, Elizabeth

Publication type:

Article

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 403, doi. 10.1007/s40273-013-0043-8

By:

Greenhalgh, Janette;
Bagust, Adrian;
Boland, Angela;
Blundell, Michaela;
Oyee, James;
Beale, Sophie;
Dundar, Yenal;
Hockenhull, Juliet;
Proudlove, Chris;
Chu, Patrick

Publication type:

Article

The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 445, doi. 10.1007/s40273-013-0041-x

By:

Refoios Camejo, Rodrigo;
McGrath, Clare;
Miraldo, Marisa;
Rutten, Frans

Publication type:

Article

Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 393, doi. 10.1007/s40273-013-0038-5

By:

Eckermann, Simon;
Willan, Andrew

Publication type:

Article

Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 415, doi. 10.1007/s40273-013-0049-2

By:

Armstrong, Nigel;
Joore, Manuela;
Asselt, Thea;
Misso, Kate;
Manning, Nathan;
Tomini, Florian;
Kleijnen, Jos;
Riemsma, Rob

Publication type:

Article

Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 369, doi. 10.1007/s40273-013-0042-9

By:

Baal, Pieter;
Meltzer, David;
Brouwer, Werner

Publication type:

Article

Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia.

Published in:

PharmacoEconomics, 2013, v. 31, n. 5, p. 377, doi. 10.1007/s40273-013-0045-6

By:

Sorich, Michael;
Wiese, Michael;
O'Shea, Rebekah;
Pekarsky, Brita

Publication type:

Article